The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Innovent Biologics
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca; BeiGene; Bristol-Myers Squibb; Hansoh; Hengrui Therapeutics; Hutchison MediPharma; Lilly Suzhou Pharmaceutical Co.; Roche
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
 
Hye Ryun Kim
Speakers' Bureau - ABL Bio; Ono Pharmaceutical; Roche/Genentech
 
Herbert H. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Yuki Shinno
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Janssen
Research Funding - Bayer; Gilead Sciences; Janssen; Japan Clinical Research Operations; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
 
Shun Lu
No Relationships to Disclose
 
Yong Fang
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer Pharma Japan. (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); Merus (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
Research Funding - Merck
 
Liyun Miao
No Relationships to Disclose
 
Tomohiro Sakamoto
Speakers' Bureau - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Janssen; Kyowa Kirin; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Tsung-Ying Yang
Consulting or Advisory Role - AstraZeneca; Takeda
Travel, Accommodations, Expenses - MERCK
 
Christophe Alfons Dooms
Consulting or Advisory Role - MSD Oncology (Inst)
Travel, Accommodations, Expenses - MSD (Inst)
 
Daniel Shao-Weng Tan
Honoraria - Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); DKSH (Inst); Genmab; Merck (Inst); Pfizer (Inst); Roche (Inst); Zymeworks
Research Funding - ACM Biolabs (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Xiuning Le
Stock and Other Ownership Interests - BlossomHill Therapeutics
Consulting or Advisory Role - Abbvie; ABION; ArriVent Biopharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Regeneron; Sensei Biotherapeutics; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals
 
Jan Christoph Brase
Employment - Employment at Bayer Consumer Care AG, Basel, Switzerland
 
Paolo Grassi
Employment - Employment at Bayer S.p.A.
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pharma Mar, S.A.; RIKEN GENESIS CO., LTD.; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Haihe Biopharma Co., Ltd.; Janssen; Lilly Japan; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)